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Abstract 41 
Carnosine and anserine are dipeptides synthesized from histidine and -alanine by carnosine 42 
synthase (ATPGD1). These dipeptides, present in high concentration in the skeletal muscle, form 43 
conjugates with lipid peroxidation products such as 4-hydroxy trans-2-nonenal (HNE).  Although 44 
skeletal muscle levels of these dipeptides could be elevated by feeding -alanine, it is unclear how 45 
these dipeptides and their conjugates are affected by exercise training with or without -alanine 46 
supplementation.  We recruited twenty physically active men, who were allocated to either  -alanine 47 
or placebo-feeding group matched for VO2 peak, lactate threshold, and maximal power (Wmax). 48 
Participants completed 2 weeks of conditioning phase followed by 1 week of exercise testing (CPET) 49 
and a single session followed by 6 weeks of high intensity interval training (HIIT).  Analysis of muscle 50 
biopsies showed that the levels of carnosine and ATPGD1 expression were increased after CPET and 51 
decreased following a single session and 6 weeks of HIIT. Expression of ATPGD1 and levels of 52 
carnosine were increased upon -alanine-feeding after CPET, while ATPGD1 expression decreased 53 
following a single session of HIIT. The expression of fiber type markers myosin heavy chain (MHC) I 54 
and IIa remained unchanged after CPET. Levels of carnosine, anserine, carnosine-HNE, carnosine-55 
propanal and carnosine-propanol were further increased after 9 weeks of -alanine supplementation 56 
and exercise training, but remained unchanged in the placebo-fed group. These results suggest that 57 
carnosine levels and ATPGD1 expression fluctuates with different phases of training.  Enhancing 58 
carnosine levels by -alanine feeding could facilitate the detoxification of lipid peroxidation products in 59 
the human skeletal muscle.  60 
New and Noteworthy 61 
Carnosine synthase expression and carnosine levels are altered in the human skeletal muscle during 62 
different phases of training. 63 
 3 
During high intensity interval training, -alanine feeding promotes detoxification of lipid peroxidation 64 
products and increases anserine levels in skeletal muscle.  65 
 66 
Introduction 67 
Carnosine (-alanine-L-histidine) is a naturally occurring histidyl dipeptide, present at high 68 
concentrations in the skeletal muscle, the olfactory bulb and the heart (14, 35, 36, 48). It is 69 
synthesized by the enzyme carnosine synthase (ATPGD1), which catalyzes the ligation of -alanine 70 
to histidine via an ATP-mediated reaction (27). The homeostasis of carnosine in skeletal muscle is 71 
maintained by a complex interplay of proton-coupled oligonucleotide transporters (PHT1 and PEPT2) 72 
that transport amino acids across the biological membrane (29, 39, 40), as well as carnosinases 73 
(CNDP1 and CNDP2), which hydrolyze carnosine to -alanine and histidine (71). Several studies 74 
have shown that -alanine acts as a rate-limiting precursor of carnosine, and oral -alanine 75 
supplementation increases carnosine levels in the human skeletal muscle (9, 12, 23, 34, 66). It has 76 
also been suggested that exercise training may augment carnosine levels in the human skeletal 77 
muscle (44, 52) (38); but there is no consensus in the literature. In one study it was reported that  8 78 
weeks of sprint cycle training increased carnosine levels in human skeletal muscle (68); however, 79 
another study using a similar protocol, reported no effect of exercise training on carnosine 80 
concentration (8).  Similarly, no effect of exercise training on carnosine levels in the human skeletal 81 
muscle was observed after another similar training intervention lasting for 10 to 16 weeks (8, 42, 43, 82 
47). Therefore, the effects of exercise on carnosine levels and the underlying mechanisms that 83 
regulate its homeostasis in the human skeletal muscle during exercise remains unclear and requires 84 
further investigation. 85 
It is widely believed that carnosine is the predominant histidyl dipeptide present in humans 86 
(14),  whereas its methylated analogue, anserine,  is  present in high concentrations in the skeletal 87 
muscle of birds and rodents (14), but not in humans (20, 46). Anserine is synthesized by the 88 
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methylation of carnosine or by the condensation of N-methyl-l-histidine with -alanine - reactions that 89 
are catalyzed by the enzymes carnosine N-methyl-transferase and ATPGD1, respectively (25). Both 90 
carnosine and anserine contains a highly-reactive amine group, which confers to them the ability to 91 
form stable conjugates with highly toxic lipid peroxidation products such as 4-hydroxy trans-2-nonenal 92 
(HNE) and acrolein (1, 15, 51). Recent studies have shown that the formation of lipid peroxidation 93 
products  are increased in the skeletal and cardiac muscle during strenuous exercise (4, 5, 18, 24, 70, 94 
75). Previous studies performed in rodents and humans have shown that the oral supplementation of 95 
carnosine increases the extrusion of carnosine-aldehyde conjugates in urine, improves renal function 96 
in obese Zucker rats (2) and improves glucose uptake in obese humans (21, 55).  Furthermore, we 97 
have recently reported that the perfusion of isolated mice hearts with carnosine protects against 98 
ischemia-reperfusion injury (6), and that in apo-E-/- mice the addition of carnosine to drinking  water 99 
decreases atherogenesis by removing reactive aldehydes (10). Collectively, these studies suggest 100 
that carnosine detoxifies and removes lipid peroxidation products that play a pathogenic role in 101 
several diseases (28, 30, 45, 50, 56, 62).  Nevertheless, the role of carnosine in removing the 102 
products of lipid peroxidation that accumulate in the skeletal muscle during exercise has not been 103 
studied.  104 
Given that -alanine supplementation increases carnosine in humans and anserine levels in 105 
birds  (12, 23, 34, 57), we examined the effects of exercise training in physically-active individuals with 106 
or without -alanine supplementation on these dipeptides in human skeletal muscle. We tested the 107 
hypothesis that -alanine supplementation increases carnosine levels during exercise training and 108 
that this increase in carnosine promotes the detoxification of toxic lipid peroxidation products 109 
generated in skeletal muscle during strenuous exercise.  110 
Materials and Methods 111 
Participant’s recruitment and characteristics. 112 
 5 
 Twenty healthy, physically-active male men were recruited for this study. Participants were informed 113 
of any potential risks of participation in the study before the distribution of a health assessment 114 
questionnaire and informed consent forms. Inclusion criteria for participation included at least 6 115 
months of not using supplements (-alanine, creatine, branched chain amino acids, chronic caffeine 116 
supplementation). This study was performed at two Centers. Participants were recruited, tested and 117 
trained at Victoria University and biochemical assays were performed at the University of Louisville. 118 
This study was approved by the Victoria University Human Research Ethics Committee (HRE13-220).  119 
Study overview 120 
The study was divided into five phases: (a) familiarization phase; (b) baseline exercise testing; (c) 121 
conditioning phase followed by 1-week of exercise testing (CPET); (d) exercise testing; and (e) high-122 
intensity interval training (HIIT) (Fig. 1). 123 
Familiarization phase.  124 
Before entering the study protocol, the participants were familiarized with the exercise testing by 125 
visiting the exercise laboratory on three separate occasions. Participants were informed of any 126 
potential risks of the study, and after consent they were asked to complete a health assessment 127 
questionnaire and informed consent. 128 
Baseline Exercise testing 129 
A week after familiarization, baseline exercise testing was performed. Exercise testing and training 130 
was conducted on a Velotron cycle ergometer (Racermate Inc., Washington, USA) and each session 131 
was separated by at least 48 h. Testing consisted of an incremental cycling protocol to exhaustion to 132 
determine lactate threshold (LT), maximal power (Wmax) peak oxygen consumption (VO2 peak), a 133 
Cycling Capacity Test (CCT), and a muscle biopsy (as described below; Table 1). Participants were 134 
then ranked for VO2 peak, and matched pairs were randomly assigned to either -alanine (CarnoSyn, 135 
sustained-release -alanine, Natural Alternatives International, San Marcos, USA) or placebo 136 
(maltodextrin, Natural Alternatives International, San Marcos, USA) supplementation. All supplements 137 
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were tested by an independent drug surveillance laboratory (HFL Sport Science, Cambridgeshire, UK) 138 
and tested negative for contamination from prohibited substances. The supplementation lasted 9 139 
weeks. It involved ingesting 6.4 g per day (two 800 mg tablets, four times daily, at least 2 h apart) of 140 
-alanine or placebo with meals or snacks. All supplements for 7 days were contained in a sealed 141 
opaque pill container and were distributed to the participants weekly by an independent individual not 142 
involved with data collection.  143 
Conditioning phase and exercise testing (CPET)  144 
During the conditioning phase (first two weeks), participants completed six cycling training sessions 145 
(separated by at least 48 h) that consisted of 1 h of cycling at 70% of their lactate threshold. The goal 146 
of this phase was to improve the exercise tolerance of all participants, and to reduce the risk for injury 147 
during the following HIIT phase.  In the third week, the participants performed a second exercise 148 
testing, which included an incremental cycling protocol to exhaustion, a CCT, and a 30-km cycling 149 
time trial (30-km TT).  150 
High intensity interval training (HIIT)  151 
After exercise testing, the participants underwent a single session of HIIT and then began an 152 
individualized 6 week HIIT program (3 sessions per week). The exercise intensity of each session was 153 
the intensity at the LT plus 40 to 90% of the difference between the LT and Wmax, in addition to each 154 
participants LT. For example, a participant with a LT and Wmax of 200 and 280 W respectively would 155 
have a training workload of 232 W, (200 + 40/100 * (280 – 200) = 232). The number of intervals for 156 
each session ranged from 4 to 14 intervals and there was a 2:1 min work to rest ratio. The training 157 
plan was designed to mimic athletic training programs and to allow progression, while preventing 158 
overtraining (Fig. 1).  159 
Physical activity and nutritional control 160 
Participants were instructed to maintain a normal dietary pattern and to keep high-intensity physical 161 
activity to a minimum throughout the entire study. To minimize within-subject variability in muscle 162 
metabolism, participants were instructed to consume identical dinners and not to have breakfast prior 163 
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to each muscle biopsy and exercise testing session. Participants were provided with a standardized 164 
dinner (50 kJ.kg-1 body mass, consisting of 60/20/20% of carbohydrate, fat and protein respectively) 165 
and breakfast (40 kJ kg-1 BM, consisting of 60/20/20% of carbohydrate, fat and protein respectively) 166 
prior to the 30-km TT, which were consumed 15 h and 3 h prior to exercise. 167 
Maximal Power, Lactate Threshold (LT) and Peak Oxygen Consumption 168 
Participants visited the exercise laboratory to perform an incremental cycling protocol to exhaustion 169 
for the purpose of determining their LT, Wmax, and VO2 peak. The test consisted of 4-min stages, 170 
separated by 30-s of rest, until voluntary exhaustion or the inability to maintain a minimum pedal 171 
cadence of 60 rpm. The participants began cycling at 60 W with an increase of 30 W for each 172 
subsequent stage. Maximal power was determined using the following equation: Wmax = Workload + 173 
(t/240) x 30 ( where t-time completed during the final stage) (37). Venous blood samples were taken 174 
at the end of each stage via intravenous cannulation and analyzed using an automated cartridge-175 
based gas analyzer (Radiometer, Copenhagen, Denmark). The LT was calculated using the modified 176 
Dmax method (13) . Expired gases were analyzed every 15-s using a metabolic cart (Moxus Metabolic 177 
System, AEI Technologies, USA), which was calibrated using known gas concentrations prior to each 178 
test (20.93% O2, 0.04% CO2 and 16.10% O2, 4.17% CO2; BOC Gases, Australia). Oxygen 179 
consumption was recorded every 15-s and the two-highest consecutive 15-s values recorded during 180 
the test were averaged and recorded as the participant’s VO2 peak. 181 
Cycling Capacity Test 182 
High-intensity exercise performance was determined by time to exhaustion and total work done 183 
(TWD) during the CCT at 110% Wmax (CCT110%). After a warmup for cycling at 100 W for 10 min, 184 
participants began cycling at a pedal cadence of 80 to 100 rpm at 80% of Wmax for 15 s before 185 
increasing to 90% for 15 s and eventually 110% of Wmax, while maintaining a seated position.  186 
Muscle biopsies 187 
Resting muscle biopsies (approximately 150 to 300 mg wet weight) were taken from the vastus 188 
lateralis muscle by an experienced medical practitioner using a Bergstrom needle. Muscle biopsies 189 
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were performed at least 48 h after the completion of baseline exercise testing, after the conditioning 190 
plus exercise testing (at rest and immediately after the first HIIT session), and after 6 weeks of the 191 
HIIT program. Participants rested in the supine position, and after injection of a local anesthetic into 192 
the skin and fascia (1% xylocaine, Astra Zeneca) a small incision was made in the vastus lateralis. 193 
Muscle samples were processed, cleaned of excess blood, fat, and connective tissue, and 194 
immediately frozen in liquid nitrogen and stored at -80°C until analysis. 195 
Preparation of carnosine-aldehyde conjugates  196 
Authentic standards for carnosine (m/z 227), anserine (m/z 241) and tyrosine-histidine (m/z 319) were 197 
used to determine the multiple reaction monitoring transitions (MRMs). Carnosine-aldehyde 198 
conjugates used as standards were prepared as described previously (7). Briefly, acrolein was 199 
synthesized by acid hydrolysis of diethyl acetal acrolein (Sigma) in HCl (0.1 M) which was kept at 200 
room temperature (RT) for 30 min. The carnosine-propanal conjugate was synthesized by incubating 201 
100 mM acrolein (10 µL) with 10 mM carnosine (990 µL) in water at RT for 2 h. Carnosine-propanol 202 
conjugate was synthesized by incubating 10 mM NaBH4 (10 µL) in water with carnosine-propanal (500 203 
µL) at RT. Carnosine-HNE conjugate was synthesized by incubating HNE (70 mM; Calbiochem) with 204 
10 mM carnosine in water (10:1) at RT. The dipeptides and carnosine-aldehyde conjugates were 205 
individually infused into a stream of 0.55 mL/min 50:50 A: B UPLC solvent going into a Waters 206 
(Milford, MA) Xevo TQ-S micro triple quadrupole mass spectrometer.  An automated optimization 207 
program IntelliStart (Waters, Milford, MA) was used to determine the optimal ionization voltages, 208 
collision energies and product ions. Maximum ionization conditions and optimal daughter ions were 209 
used to program sensitive MRMs.  210 
Identification of histidyl dipeptides and carnosine-aldehyde conjugates by LC/MS/MS 211 
Skeletal muscle biopsies from participants were homogenized in an extraction solution containing 10 212 
mM HCl and 200 µM tyrosine-histidine as an internal standard (IS). The tyrosine-histidine was 213 
purchased from Bachem. Homogenates were sonicated on ice for 10 s, centrifuged at 16,000xg for 10 214 
min and supernatant was diluted with 3 volumes of ice-cold acetonitrile. Before analysis, the samples 215 
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were vortexed thoroughly to precipitate proteins, kept on ice for 15 min, and then centrifuged at 216 
16,000 x g for 10 min at 4˚C. The supernatants were stored at -20˚C for further processing. Prior to 217 
injection into TQ-S micro mass spectrometer in positive mode, the samples were diluted in 75% 218 
acetonitrile: 25% water. Dipeptides and their aldehyde conjugates were separated and identified by 219 
using Waters ACQUITY UPLC H-Class System coupled with a Xevo TQ-S micro triple quadrupole 220 
MS.  The analytes were separated by a Waters Acquity BEH HILIC column (1.7µm, 2.1x50 mm) 221 
equipped with an in-line frit filter unit. The analytes were eluted by using a binary solvent system 222 
consisting of 10 mM ammonium formate, 0.125% formic acid in 50% acetonitrile: 50% water for 223 
mobile phase A and 10 mM ammonium formate 0.125% formic acid in 95% acetonitrile: 5% water for 224 
mobile phase B at a flow rate of 0.55 mL/min. Initial conditions were 0.1: 99.9 A: B ramping to 99.9: 225 
0.1 A:B over 5 min then quickly ramping to 0.1:99.9 A:B over 0.5 min. This initial composition was 226 
held from 5.5-8 min to equilibrate the column for the next injection. Dipeptides were quantified using 227 
the LC/MS calibration curve of relative area of carnosine and anserine to tyrosine-histidine (IS), and 228 
their aldehyde conjugates were quantified using the peak ratio of histidyl-dipeptide and tyrosine-229 
histidine (IS) and expressed as mole/mg wet weight. For carnosine m/z 227110, anserine m/z 230 
241109, carnosine-HNE m/z 383110, carnosine-propanal m/z 283110, carnosine-propanol m/z 231 
285110 and tyrosine-histidine m/z 319110, MRM transitions were followed. We recorded the 232 
abundance of at least four confirmation transitions for each molecule. 233 
The precision of the LC/MS/MS method was validated by replicate analysis of the samples 234 
with highest and lowest concentrations of the analytes. Homogenates were pooled from lowest (1 mL) 235 
(n=10) and highest (1 mL) carnosine concentration samples (n=10). Five aliquots from each sample 236 
were processed and analyzed each day for three consecutive days. Relative variability was calculated 237 
by calculating the coefficient of variation (CV) of replicates within one sample run and between 238 
different sample runs as described by Chesher (19). The variability of inter- and intra-assay for 239 
carnosine low was 3.4%, carnosine high 4.92%, anserine low 9.95%, anserine high 6.87%, carnosine-240 
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propanal low 8.07%, carnosine-propanal high 6.25%, carnosine-propanol low 4.14%, carnosine-241 
propanol high 5.96%, carnosine-HNE low 12.14% and carnosine-HNE high 16.46%. The lower limit of 242 
quantification (LOQ) for carnosine was 19 nM, anserine 24 nM, carnosine-propanal 275 nM, 243 
carnosine-propanol 261 nM and carnosine-HNE 257 nM. 244 
Western blot analysis 245 
Skeletal muscle biopsies collected from participants at different stages of training (n=4-8 in each 246 
group) were homogenized in RIPA buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1mM 247 
EGTA, 1% NP-40). Homogenates were centrifuged for 25 min at 13,000g and the supernatants were 248 
separated by SDS-PAGE. Immunoblots were analyzed using anti-ATPGD1, anti-CNDP2, anti-PHT1 249 
anti-PEPT2, anti-glyceraldehyde 3-phosphate (GAPDH), anti-myosin heavy chain (MHCI) and MHCIIa 250 
antibodies. Antibodies were purchased from Abcam and Thermo-fisher. Western blots were 251 
developed using HRP substrate (ECL plus from Pierce) and scanned with Typhoon Bioimager (GE 252 
healthcare). Band intensity was quantified by using Image Quant TL software (Amersham 253 
Biosciences) that were normalized to GAPDH and Amido-black staining.  254 
Statistical Analyses 255 
Differences in histidyl dipeptides and histidyl-dipeptide conjugates between groups (-alanine vs 256 
placebo) and times (week) were estimated using linear mixed-effects models with a group and time 257 
interaction variable. Statistical analyses were performed using SAS, version 9.4, software (SAS 258 
Institute, Inc., Cary, North Carolina). For Western blot analysis, a one-way ANOVA was used followed 259 
by Bonferroni corrections. Statistical analysis was done using GraphPad analysis software. Statistical 260 
significance was accepted at p<0.05. Group data are presented as meanstandard deviation (SD).  261 
Results 262 
 Exercise training in combination with -alanine feeding increases carnosine levels  263 
To examine whether exercise training in combination with or without -alanine supplementation 264 
could affect carnosine levels in the human skeletal muscle, we collected muscle biopsies from the 265 
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participants at different phases of training, and analyzed for carnosine by LC/MS/MS. We identified 266 
carnosine in the skeletal muscle on the basis of retention time, MRMs, and fragmentation pattern, 267 
which accurately matched with the ex-vivo carnosine standard (Fig. 2 A, B). Our results showed that 268 
at baseline, the levels of carnosine in the skeletal muscle were not statistically different between the 269 
placebo (6.68  1.81 nmol/mg tissue) and the -alanine-fed groups (6.32  1.41 nmol/mg tissue; Fig. 270 
2 C, E). In the placebo-fed group, the levels of carnosine after 2 weeks of conditioning followed by 1 271 
week of exercise testing (CPET) were increased 24% (8.31  1.92 nmol/mg tissue) compared with 272 
the baseline (p<0.05). However, carnosine levels were decreased after 6 weeks of HIIT compared 273 
with the CPET (6.01  1.34 nmol/mg tissue; p<0.05, Fig. 2 C, E). The carnosine levels in all the 274 
participants, except one was decreased, which was included in the analysis.  In the -alanine-fed 275 
group, the levels of carnosine after CPET were increased by 51% (9.53  1.33 nmol/mg tissue; 276 
p<0.0001) compared with the baseline (Fig. 2 C, E) and reached 14.40  4.38 nmol/mg tissue after an 277 
additional 6 weeks of HIIT leading to a total 127% increase in muscle carnosine over the 9 week 278 
supplementation period and 140% compared with the placebo fed group. Carnosine concentration in 279 
the placebo-fed group was decreased following a single session of HIIT (6.74  1.94 nmol/mg tissue) 280 
compared with the CPET (p<0.05) whereas its concentration in the -alanine fed group increased 281 
66% compared with the baseline (10.51  2.82 nmol/mg tissue; p<0.001) and 10% compared with 282 
pre-HIIT (Fig. 2 D, F).  Collectively, these results demonstrate that carnosine levels fluctuate during 283 
different phases of training (in the placebo fed condition) and further confirms the potent effect of 284 
chronic -alanine supplementation on muscle carnosine loading when combined with high-intensity 285 
exercise training.  286 
ATPGD1 expression in the skeletal muscle is altered during different phases of exercise training 287 
Given that the carnosine levels were elevated in the skeletal muscle after 2 weeks of 288 
conditioning followed by 1 week of exercise testing (CPET) and decreased after a single session and 289 
6 weeks of HIIT, we next investigated whether there were any changes in the expression of enzymes 290 
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(ATPGD1 and CNDP2) or transporters (PHT1 and PEPT2) that determine carnosine levels in the 291 
skeletal muscle (27, 29, 39, 40, 71). Our results showed that in the placebo-fed group, ATPGD1 292 
expression increased 1.5-fold after CPET compared with the baseline, which was decreased 293 
following a single session and 6 weeks of HIIT (Fig. 3 A, B, C). We next determined whether ATPGD1 294 
could respond to exercise stimulus, in the -alanine-fed group and found that its expression was 295 
increased 1.2-fold after CPET compared with the baseline and decreased following a single session 296 
of HIIT (Fig. 3 D, E). Expression of PHT1 and CNDP2 remained unchanged in all the groups at 297 
different phases of training (Fig. 3 A B, D, E).  PEPT2 was not detected in these tissues. To examine 298 
whether changes in ATPGD1 expression and carnosine levels could be due to a shift in fiber type 299 
during exercise, we next compared the expression of fiber type markers MHC I and IIa in tissues 300 
collected at baseline and after CPET.  In comparison with the baseline, the expression of both MHCI 301 
and IIa remained unchanged after CPET (Fig. 3 F) suggesting that the changes in ATPGD1 302 
expression and carnosine levels during exercise could not be attributed to changes in fiber types. 303 
Collectively these results suggest that ATPGD1 responds to exercise stimulus and thus could be an 304 
important regulator to maintain carnosine levels in the skeletal muscle during exercise.  305 
-alanine feeding in combination with exercise training increases anserine level in the human skeletal 306 
muscle  307 
To examine whether -alanine could also increase anserine levels, we first examined whether 308 
anserine is present in human skeletal muscle. Our LC/MS/MS analysis of human skeletal muscle 309 
detected anserine, which had a similar retention time, MRMs and fragmentation pattern to the ex-vivo 310 
anserine standard (Fig. 4 A, B). Our results showed that anserine levels at baseline were similar in the 311 
placebo-(0.111  0.025 nmol/mg tissue) and -alanine-fed groups (0.101  0.019 nmol/mg tissue), 312 
which were increased 29% after 9 weeks of -alanine feeding compared with the placebo-treated 313 
group (0.122  0.024 vs 0.095  0.015 nmol/mg tissue; p<0.05 Fig. 4 C, E).  However, after 6 weeks 314 
of HIIT, the levels of anserine in the -alanine-fed group were 20 % higher than its baseline values 315 
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(p<0.05) and after CPET (0.111  0.023 nmol/mg tissue p<0.05). Anserine levels were decreased in 316 
the -alanine fed group following a single session of HIIT compared to CPET, except one participant 317 
that was included in the analysis, however the differences between the two groups did not reach to 318 
statistical significance (0.097 0.022 nmol/mg tissue, p<0.13). No changes in anserine levels were 319 
observed in the placebo fed group following a single session of HIIT (Fig. 4 D, F).  320 
Carnosine promotes detoxification of lipid peroxidation products in human skeletal muscle  321 
Because, strenuous exercise has been reported to increase the production of lipid 322 
peroxidation products in both cardiac and skeletal muscle (4, 5, 18, 24, 70, 75), we next examined 323 
whether  the increase in carnosine levels in the skeletal muscle following -alanine supplementation 324 
could scavenge these products.  Our analysis of the skeletal muscle biopsies showed that at baseline, 325 
the skeletal muscle had detectable levels of carnosine-aldehyde conjugates, carnosine-HNE (m/z 326 
385; Fig. 5 A, B), carnosine-propanal (m/z 283; Fig. 5 C, D), and carnosine-propanol (m/z 285; Fig. 5 327 
E, F), identified on the basis of their retention time, MRM, and fragmentation pattern. 328 
When we analyzed the skeletal muscle, biopsies collected after 6 weeks of HIIT, we found 329 
that carnosine-HNE levels were significantly higher (58%) in the -alanine-fed group than in the 330 
placebo-fed group (-alanine: 480  214 vs placebo: 303  178 fmols/mg tissue, p<0.05; Fig. 6 A, B). 331 
The levels of the aldehyde conjugates in the -alanine-fed group after 9 weeks of -alanine feeding 332 
and exercise training were increased 104% compared with their baseline (480  214 vs 236  94 333 
fmols/mg tissue; p<0.0009) and 48% compared with the values recorded at CPET (325  146 334 
fmols/mg tissue; p<0.04; Fig. 6 A, B). Similarly, the generation of carnosine-propanal after 6 weeks of 335 
HIIT was significantly increased in the -alanine-fed group (119%) compared with the placebo-fed 336 
group (-alanine; 980  445 fmols/mg tissue vs placebo: 446  114 fmols/mg tissue; p<0.005; Fig. 6 337 
E, F). The levels of carnosine-propanal in the -alanine-fed group after 9 weeks of feeding increased 338 
88% compared with the baseline (521  224 fmols/mg tissue; p<0.001) and 68% compared with the 339 
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CPET (580  130 fmols/mg tissue; p<0.007; Fig. 6 E, F). No changes in these conjugates were 340 
observed following the first session of HIIT (Fig. 6 C, D, G, and H). 341 
We had previously reported that carnosine-propanal is enzymatically reduced by aldose reductase 342 
(AR) to carnosine-propanol, and, in humans, carnosine-propanol is the most abundant carnosine-343 
aldehyde conjugate extruded in urine (7). In agreement with these results, we found that carnosine-344 
propanol was the most abundant carnosine-aldehyde conjugate (10.90  4.02 pmols/mg tissue) 345 
present in the human skeletal muscle. The levels of carnosine-propanol after 6 weeks of HIIT in the  346 
-alanine fed group increased ~86% compared with the placebo-fed group (-alanine: 17.62  8.74 347 
pmols/mg tissue vs placebo: 9.48  3.39 pmols/mg tissue; p<0.001 Fig. 6 I, J).  After 9 weeks, in the 348 
-alanine-fed group, the levels of carnosine-propanol conjugates were ~43% higher than their 349 
baseline concentration (12.30  6.90 pmols/mg tissue; p<0.06) and ~40% compared with the CPET 350 
(12.49 6.09 pmols/mg tissue; p<0.06 Fig. 6 I, J) respectively. No changes in these aldehyde 351 
conjugates was observed after a single session of HIIT (Fig.  6 K, L).  352 
 353 
Discussion 354 
The major findings of this study are that low intensity endurance exercise training increases 355 
carnosine levels, which were decreased after high intensity interval training, and that the magnitude of 356 
this increase is augmented by -alanine supplementation. The study also reports, for the first time that 357 
significant levels of anserine are present in human skeletal muscle, and that like carnosine, the levels 358 
of anserine also increase upon -alanine supplementation. This increase in histidyl dipeptides levels 359 
was accompanied by a parallel increase in their synthetic enzyme–ATPGD1, without significant 360 
changes in the abundance of PHT1 and CNDP2 or in MHC1 and IIa, suggesting that changes in the 361 
levels of histidyl dipeptides upon exercise and -alanine supplementation could not be attributed 362 
either to changes in skeletal muscle transport of the peptides and their precursors or to changes in 363 
fiber type composition of the muscle.  Importantly, we found that the increase in carnosine upon -364 
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alanine feeding and exercise led to a corresponding increase in several conjugates of carnosine with 365 
the toxic products of lipid peroxidation such as HNE and acrolein.  Taken together, these findings 366 
support the notion that carnosine levels and ATPGD1 expression are altered during different phases 367 
of exercise training and -alanine feeding increases carnosine levels by stimulating its synthesis, and 368 
that this increase in carnosine may have a protective role in preventing skeletal muscle damage due 369 
to lipid peroxidation products generated as a result of increased oxidative stress during vigorous 370 
exercise. 371 
Previous studies have reported that the concentration of carnosine in the human skeletal 372 
muscles ranges from  5-8 mmol.kg-1 of wet muscle (14, 35, 52) or 20-30 mmol.kg-1 in dry muscle (22, 373 
31, 34). In this study, we found that carnosine levels in human skeletal muscle were within the range 374 
(6.550.44 mmol.kg-1 wet weight) reported by other investigators. The levels of carnosine in skeletal 375 
muscle, while high, could be increased further by prolonged exercise. Previous studies suggest that 376 
training may augment carnosine levels in the human skeletal muscle (38, 44, 52, 69). Our analysis of 377 
the skeletal muscle showed that the carnosine levels were increased ~24% after CPET, which were 378 
decreased following a single session and after 6 weeks of HIIT. In the  -alanine-fed group, carnosine 379 
levels in the skeletal muscle were increased by ~40% after 3 weeks and ~140% after 9 weeks of -380 
alanine supplementation, which are comparable with previous reports showing that carnosine 381 
concentration in the skeletal muscle increased by ~40% after 4 weeks and by ~80% after 10 weeks of 382 
-alanine feeding either in combination with training or alone (23, 34, 42). Collectively these results 383 
indicate that -alanine supplementation is required to increase carnosine levels during the long-term 384 
and stimulus from low endurance training and HIIT could alter carnosine levels, in the skeletal muscle. 385 
Several mechanisms could account for the increase in carnosine levels in the skeletal 386 
muscle after exercise. Carnosine levels in the skeletal muscle could increase due to greater uptake of 387 
its precursors – -alanine and histidine, or by the uptake of carnosine in the plasma into the skeletal 388 
muscle.  Because different fiber types contain different levels of carnosine(59), carnosine levels in the 389 
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muscle could also change due to a change in fiber type. However, our results showed that exercise 390 
training, at least, under the protocol used for this study, did not affect peptidyl transporters such as 391 
PHT1, hydrolases CNDP2, nor did it affect the levels of MHCI or MHCIIa, suggesting that neither an 392 
increase in transport and hydrolysis, nor a change in fiber type can account for the increase in 393 
carnosine levels after exercise.  In contrast, our results showing that elevated carnosine levels in the 394 
skeletal muscle were accompanied by a greater abundance of its synthetic enzyme – ATPGD1 in both 395 
the placebo and -alanine fed groups, provides circumstantial evidence that exercise increases 396 
carnosine levels in skeletal muscle by stimulating its synthesis, rather than its transport or uptake.  397 
Although we did not see an increase in the abundance of peptide transporter proteins in the 398 
skeletal muscle, it is possible that the carnosine levels in the skeletal muscle could be elevated due to 399 
greater supply of carnosine in the plasma, potentially due to increased consumption of carnosine 400 
containing foods such as red meat.  This seems unlikely because the participants of our study were 401 
requested not to change their diet.  Nonetheless, even if the participants did not comply with our 402 
instructions, the magnitude of the increase observed in our study could not be accounted by 403 
increased consumption of red meat alone.  The average meat consumed by Australians is  280 g per 404 
day and the carnosine concentration in red meat is  450mg /100 g (23, 54), suggesting  that the  405 
average intake of carnosine per day is 1.3 g, which is 4-5 fold less than that needed to increase 406 
carnosine levels in the skeletal muscle within 21 days as seen in our study.  Thus, an increase in 407 
carnosine levels in the skeletal muscle most likely appears to be due to an increase in ATPGD1 408 
expression. That both carnosine and ATPGD1 levels were decreased in tandem after 6 weeks of HIIT, 409 
further reinforces the apparently close relationship between carnosine levels and ATPGD1 abundance 410 
in the skeletal muscle.  We did not pursue to measure ATPGD1 expression after 6 weeks of HIIT in 411 
the -alanine-fed group, because carnosine levels remained significantly elevated in this group due to 412 
-alanine feeding. However, despite this finding, the mechanisms by which exercise increases the 413 
expression of ATPGD1 were not elucidated in the present study. Because the ATPGD1 expression 414 
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was increased in both the placebo and -alanine fed humans, it is tempting to speculate that the 415 
enzyme could be regulated by transcription factors that respond to exercise.  However, this increase 416 
in ATPGD1 was not sustained, and the abundance of the protein decreased after a single session and 417 
6 weeks of HIIT in the placebo fed group. One possible explanation for the decrease in ATPGD1 418 
protein levels could be that the protein degradation pathways such as autophagy or ubiquitin-419 
proteasome are activated following HIIT. Previous studies using animal models have provided 420 
evidence that a single intense bout of forced treadmill or endurance training activates autophagy in 421 
both the skeletal and cardiac muscle (33) (17). Similarly, it has been shown that in healthy, trained 422 
humans, a single session of maximal eccentric resistance exercise induces autophagy and decreases 423 
the expression of actin crosslinking protein filamin C gamma in the skeletal muscle (74). Collectively 424 
our studies indicate that the changes in carnosine levels during different phases of exercise training 425 
mirrors the ATPGD1 expression suggesting that this enzyme is one of the important regulators to 426 
maintain carnosine levels. 427 
The lack of increase in carnosine levels after 6 weeks of HIIT in our study is in contrast to a 428 
recent report by Painelli et.al.(58) showing that the levels of carnosine are increased in the vastus 429 
laterals muscle of vegetarians after 12 weeks of HIIT, accompanied by a decrease in MHCI and an 430 
increase in MHC IIa,  with no change in ATPGD1 gene expression. In contrast to these findings, we 431 
found that the expression of MHCI and IIa fibers remained unaltered after CPET, suggesting that the 432 
increase in carnosine levels and ATPGD1 expression after CPET is independent of shifts in fiber type. 433 
The reasons for these divergent results are not clear. However, this apparent disparity may be related 434 
to differences in HIIT duration between the two studies. Our study was limited to 6 weeks, while in the 435 
Painelli; study, a 12 week HIIT was used. Thus, a longer duration of exercise training, which led to 436 
changes in fiber type could lead to a secondary, fiber-type dependent, increase in carnosine, 437 
unrelated to changes in ATPGD1 levels.   Despite these differences, both the studies indicate that the 438 
carnosine responds to the stimulus induced by exercise training, but further work is required to 439 
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delineate the mechanisms that lead to an increase and decrease in the carnosine levels during early 440 
and  late phases of adaptation to exercise respectively. 441 
In addition to carnosine, skeletal muscle of different animals shows a wide variety of histidyl 442 
dipeptides such as carcinine, homocarnosine, anserine, ophidine, and acetylcarnosine (14).   443 
Reasons for such diversity of peptides remains unclear. Nonetheless, previous work has shown that 444 
anserine, which is the methylated analogue of carnosine  is the  predominant histidyl dipeptide 445 
present in the avian skeletal muscle  (14), whereas in human skeletal muscle, carnosine is believed to 446 
be the sole histidyl dipeptide (20, 46). However, our LC/MS/MS analysis showed that in addition to 447 
high levels of carnosine, anserine could also be detected in human skeletal muscle at a concentration 448 
of 0.1060.003 mmol.kg-1 wet muscle, which accounts for approximately 2% of the total histidyl 449 
dipeptide content of the muscle. This is consistent with other mammalian species, nearly all of which 450 
synthesize anserine, in addition to carnosine. However, anserine had not been detected in previous 451 
study with human muscle, which may be due to the lack of a sensitive and selective methods of 452 
detection(46). The LC/MS/MS method used in the present study was sensitive enough for the 453 
quantification of 10 fmol of anserine in the skeletal muscle and it also provided unambiguous 454 
structural identification of the dipeptide, which is not possible with the previous measurement 455 
techniques such as HPLC attached with UV detector.  In this regard, it is important to point out that a 456 
catalytically active analog of the avian carnosine N-methyltransferase - UPF0586 is expressed in 457 
humans (26), which further supports the possibility that humans can synthesize anserine from 458 
carnosine.  459 
We found not only that anserine was present in human skeletal muscle, but that its levels 460 
were increased (to 0.122  0.024 mmol.kg-1) after -alanine supplementation combined with the 461 
exercise training. Because anserine is synthesized by the methylation of carnosine (catalyzed by 462 
carnosine-N-methyltransferase) (25), it is not surprising that the levels of both these peptides change 463 
in parallel.  Moreover, even though the magnitude of relative increase in anserine after 9 weeks of -464 
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alanine feeding was lower (~20%) than the increase in carnosine (~130%), the anserine levels were 465 
significantly higher compared with the placebo-fed group. Because  anserine is not rapidly hydrolyzed 466 
by serum carnosinase (11, 53), its increase might provide benefits not provided by an increase in 467 
carnosine. That supplementation of anserine/carnosine (3:1) to elderly people preserves verbal 468 
episodic memory (41) , suggests that it may have potent salutary effects in humans.  However, 469 
additional studies are warranted to test whether anserine could be more beneficial than carnosine, 470 
whose effectiveness may be limited by serum carnosinase (71).  471 
A major finding of our study is that the increase in carnosine levels in the skeletal muscle 472 
was accompanied by elevated levels of several conjugates of carnosine with lipid peroxidation 473 
products such as acrolein and HNE.   Previous studies have shown that strenuous exercise increases 474 
the production of reactive oxygen species (ROS), which lead to increased peroxidation of unsaturated 475 
fatty acids in the membrane (4) (5, 24, 70).  Peroxidation of membrane lipids results in the formation 476 
of stable end-products such as HNE and acrolein, which are believed to be toxic second messengers 477 
that amplify and prolong tissue damage under oxidative stress (49, 60, 65).  That the production and 478 
accumulation of lipid peroxidation products is increased in skeletal muscle after exercise is supported 479 
by the observation that protein-HNE adducts accumulate in the skeletal muscle during strenuous 480 
exercise (4, 5, 75). By themselves, lipid peroxidation products such as HNE are highly toxic, and 481 
therefore to minimize their toxicity and protein-modification reactions, most tissue metabolize HNE 482 
and related aldehyde via several enzymatic pathways catalyzed by aldehyde dehydrogenases 483 
(ALDHs) and aldo-keto reductases (AKRs) (62-64).  When overexpressed in skeletal muscle ALDH2 484 
(32, 61, 72) has been reported to stimulate the removal of HNE during an exercise challenge (75), 485 
suggesting that this pathway is indeed an important mode of eliminating HNE and related aldehydes. 486 
Nevertheless, in addition to enzymatic detoxification, reactive aldehydes such as HNE are also 487 
removed by carnosine and anserine (1, 2, 15, 35).  Therefore, our studies showing that the oral intake 488 
of -alanine and HIIT increased the abundance of carnosine-HNE, carnosine-propanal, and 489 
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carnosine-propanol conjugates supports the hypothesis that lipid peroxidation products could 490 
accumulate in the human skeletal muscle during intense exercise and that carnosine could facilitate 491 
their detoxification by forming covalent adducts with the aldehydes.  This is further supported by data 492 
published by Carvalho et.al showing that HIIT and -alanine supplementation increases the levels of 493 
carnosine-acrolein conjugates (m/z 303) in skeletal muscle (16).  Reactive aldehydes such as HNE 494 
and acrolein are generated by the oxidation of polyunsaturated fatty acids, whereas acrolein could 495 
also be generated from the oxidation of amino acids by myeloperoxidase (3), metabolism of biogenic 496 
amines, (73), tobacco smoke, diesel exhaust, and several foods (67). Hence, our results showing that 497 
exercise training increases carnosine-propanal and carnosine-propanol suggests that in addition to 498 
lipid peroxidation, inflammation and biogenic amine metabolism could also contribute to the 499 
generation of these conjugates during exercise training.  We had previously reported that the 500 
carnosine-propanal conjugate is metabolized to carnosine-propanol by a reductive reaction catalyzed 501 
by aldose reductase. In humans, carnosine-propanol is the predominant form of the carnosine-502 
aldehyde conjugate that is extruded out in urine. Therefore, our present data showing that carnosine-503 
propanol is the predominant conjugate in the skeletal muscle further extends the concept that 504 
reduction of carnosine-aldehyde conjugates by aldose reductase is an important step in the metabolic 505 
transformation of these conjugates (7). Taken together, our observations and reports from other 506 
laboratories suggest that -alanine feeding enhances the generation of carnosine-aldehyde 507 
conjugates and thus enhancing carnosine levels in the skeletal muscle could potentially ameliorate 508 
the toxic effects of reactive aldehydes during strenuous exercise.  509 
In conclusion, the results of this study suggest that carnosine levels and ATPGD1 510 
expression are altered during different phases of exercise training and ATPGD1 could regulate 511 
carnosine homeostasis in the human skeletal during exercise. These findings demonstrate and 512 
confirm the efficacy of -alanine in enhancing carnosine and reveals its potential to act as a precursor 513 
for anserine during long-term exercise trainings. Our finding that β-alanine feeding and exercise 514 
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training increase the levels of carnosine-aldehyde conjugates in the skeletal muscle suggests that -515 
alanine supplementation, in addition to its potential effects on exercise capacity, might be an effective 516 
strategy to diminish the aldehyde-induced toxicity in the skeletal muscle during strenuous exercise.   517 
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 741 
 Figure Legends  742 
Fig.1 Experimental design. Twenty physically-active individuals (n=20) were familiarized with all 743 
exercise testing followed by the assessment of baseline characteristics, these included the lactate 744 
threshold (LT), peak oxygen consumption (VO2 peak), maximal power (Wmax) and a cycling capacity 745 
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test at 110% Wmax (CCT 110%). Participants then underwent a 2 week conditioning phase (1 h at 70% 746 
LT, 3 times per week), followed by a repeat of all baseline exercise testing plus a 30-km cycling time 747 
trial (30-Km TT), in week 3. Participants then began high-intensity interval training (HIIT, 2:1 min work 748 
rest ratio at 40% difference between LT and Wmax) at the start of week 4. From weeks 4 to 9 749 
participants completed HIIT 3 times per week for a total of 17 sessions. Muscle biopsies were 750 
collected at baseline, at rest after the 2 week conditioning phase followed by 1 week exercise testing, 751 
immediately following the first session of HIIT (at the start of week 4), and after 6 weeks of HIIT.  752 
Fig. 2 Carnosine levels are altered in the skeletal muscle during different phases of training in 753 
the placebo fed group and enhanced in the -alanine group. Representative single ion 754 
chromatogram of (A) carnosine in the skeletal muscle of one participant involved in the study (i) inset 755 
shows the fragmentation pattern of carnosine in the skeletal muscle (B) representative fragmentation 756 
pattern of ex-vivo carnosine standard. Individual levels of carnosine (C) at baseline, after CPET (3) 757 
and after 6 weeks of HIIT in the -alanine and placebo-fed groups (9). (D) Individual carnosine levels 758 
after CPET (3), followed by a single session of high intensity interval training (3’) in the -alanine and 759 
placebo-fed groups. (E, F) Absolute values of carnosine in the placebo and -alanine-fed groups; data 760 
is presented as mean  SD, n=10 subjects in each group. *p<0.01 vs baseline (placebo), p<0.01 vs 761 
baseline (-alanine), #p<0.05 vs 9 weeks of placebo, $p<0.01 vs 3 weeks of -alanine, +p<0.001 vs 3’ 762 
weeks of placebo-fed group. 763 
Fig. 3 Carnosine synthase (ATPGD1) expression is enhanced after 2 weeks conditioning phase 764 
followed by 1 week of exercise testing (CPET) and decreased after high intensity interval 765 
training (HIIT). Representative Western blots of ATPGD1, proton/histidine transporter (PHT1), and 766 
carnosinase (CNDP2), in the skeletal muscle biopsies obtained from the (A) placebo and (D) -767 
alanine-fed groups at baseline, after CPET and followed by a single session of HIIT (3’ HIIT). Bands 768 
normalized to amido-black (AB) and (B, E) data are presented as mean SD, n=4 samples in each 769 
group. (C) ATPGD1 expression in biopsies collected from placebo-fed group after CPET and after 6 770 
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weeks of HIIT. Bands were normalized to GAPDH and lower panel shows the quantitative analysis of 771 
ATPGD1. Data are presented as mean  SD, n = 4-8 samples in each group. (F) Western blots of 772 
MHC I and II at baseline and after CPET from placebo-fed group. Lower panel shows the quantitative 773 
analysis of MHCI and II normalized to GAPDH. Data are mean  SD, n=4-8 in each group, * p<0.05 vs 774 
baseline and, # p<0.05 vs CPET. 775 
Fig. 4  -alanine feeding combined with exercise enhances anserine levels in the human 776 
skeletal muscle. Representative single ion chromatogram of (A) anserine in the skeletal muscle of 777 
one participant involved in the study, (i) inset shows the fragmentation pattern of anserine present in 778 
skeletal muscle. (B) Representative fragmentation pattern of the ex-vivo anserine standard. Individual 779 
anserine levels (C) at baseline, after the 2 week conditioning phase followed by 1 week of exercise 780 
testing (CPET) (3) and after 6 weeks of high intensity interval training (HIIT) in the -alanine- and 781 
placebo-fed groups (9). (D) Individual anserine levels after CPET (3) followed by a single session of 782 
HIIT (3’). (E, F) Mean  SD of anserine in the placebo- and -alanine-fed groups. N=10 participants in 783 
each group, *p<0.01 vs pre-supplementation (placebo), #p<0.05 vs 9-weeks of placebo 784 
supplementation, $p<0.05 vs 3-weeks of -alanine supplementation. 785 
Fig.5 Tandem mass spectra (MS/MS) of carnosine-aldehyde conjugates detected in the human 786 
skeletal muscle and ex-vivo. Representative single ion chromatogram from one participant involved 787 
in the study and fragmentation pattern of conjugates synthesized in-vitro (A, B) carnosine-HNE (C, D) 788 
carnosine-propanal and (E, F) carnosine-propanol. 789 
Fig. 6 Carnosine-aldehyde conjugates are enhanced by -alanine feeding. Individual levels and 790 
absolute values of  (A, B) carnosine-HNE (m/z 383), (E, F) carnosine-propanal (m/z 283), and (I, J) 791 
carnosine-propanol (m/z 285) detected in the human skeletal muscle by LC/MS/MS at baseline, after 792 
2 weeks of conditioning phase followed by 1 week of exercise testing (CPET) (3), and after  6 weeks 793 
of HIIT in the placebo and -alanine fed groups (9). Individual and absolute values of (C, D) 794 
carnosine-HNE, (G, H) carnosine-propanal and (K, L) carnosine-propanol after CPET (3), followed by 795 
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a single session of HIIT (3’). Data are presented as meanS.D, n=10 subjects in each group, * p<0.05 796 
vs baseline (-alanine-fed group), # p<0.05 vs 9-weeks of placebo feeding, # p<0.05 vs 3-weeks of -797 
alanine feeding.  798 
Table. 1 Participant characteristic  799 
Characteristic of the participants (n=20), age (y), mass (kg), peak oxygen consumption (VO2 peak), 800 
lactate threshold (LT) and maximal power (Wmax). 801 
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Placebo                  β-alanine                          Placebo                β-alanine 
Characteristic                                   Group 
         Placebo (n = 10) β-alanine (n=10) 
Age (y) 25.3 ± 7.7 29.4 ± 7.0 
Mass (kg) 78.7 ± 10.8 71.4 ± 10.5 
VO2peak  
(mL.min-1.kg-1) 
53.1 ± 7.9 53.1 ± 9.0 
Lactate threshold (LT) 201 ± 50 204 ± 59 
Wmax (W) 285 ± 49 282 ± 65 
Table 1 
